Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Baseline mean tumor size was 9.2 cm (range, 4 to 32 cm). pCR occurred in breast in 11 patients (23%; 95% CI, 12% to 37%) and breast and axilla in eight patients (17%; 95% CI, 8% to 30%). pCR rates in breast (HER2 positive, seven of 30 patients, 23% v HER2 negative, four of 18 patients, 22%; P > .05) and breast and axilla (four of 30 patients, 13% v four of 18 patients, 22%, respectively; P > .05) were similar regardless of HER2 status by fluorescence in situ hybridization (FISH). At a median follow-up time of 43 months, 4-year progression-free survival (PFS) rate was 81% (95% CI, 64% to 90%); overall survival (OS) rate was 86% (95% CI, 71% to 94%). In patients with pCR in breast and axilla, PFS and OS rates were 100% (95% CI, inestimable). In patients without pCR, PFS rate was 76% (95% CI, 57% to 88%; P = .15, log-rank test), and OS rate was 83% (95% CI, 66% to 92%; P = .21). Survival rates were similar regardless of FISH status. There were only two grade 4 adverse events. CONCLUSION:
|
Authors | Judith Hurley, Philomena Doliny, Isildinha Reis, Orlando Silva, Carmen Gomez-Fernandez, Pedro Velez, Giovanni Pauletti, Jodeen E Powell, Mark D Pegram, Dennis J Slamon |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 24
Issue 12
Pg. 1831-8
(Apr 20 2006)
ISSN: 1527-7755 [Electronic] United States |
PMID | 16549824
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Taxoids
- Docetaxel
- Receptor, ErbB-2
- Trastuzumab
- Cisplatin
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Cisplatin
(administration & dosage)
- Disease Progression
- Docetaxel
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Receptor, ErbB-2
(analysis)
- Survival Analysis
- Taxoids
(administration & dosage)
- Trastuzumab
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|